IO Biotech

IOBT41

Penny Stock

$0.89arrow_drop_down10.31%-$0.10

Penny Stock

IOBT41

$0.89

arrow_drop_down10.31%-$0.10

Penny Stock

Performance History

Key Stats
Open	$1.00
Prev. Close	$0.97
EPS	-1.26
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$62.58M
PE Ratio	-

	LOW	HIGH
Day Range	0.88	1.00
52 Week Range	0.73	2.09

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.26

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About IO Biotech (IOBT)

IO Biotech, Inc. (IOBT) is a biotechnology company focused on developing novel immune therapies for the treatment of cancer and other infectious diseases. The company's proprietary platform utilizes the body's natural immune response to target and eliminate disease-causing cells. IOBT's lead product candidate is an immunotherapy designed to activate the immune system to recognize and attack tumor cells. The therapy has shown promising results in preclinical and clinical studies, demonstrating the potential to improve patient outcomes and survival rates.

The stock price history of IO Biotech, Inc. (IOBT) has shown steady growth over the past year. The stock has experienced fluctuations in response to market conditions and company news, but overall has demonstrated a positive trend. Investors have recognized the potential of IOBT's innovative approach to cancer treatment and are optimistic about the company's future prospects.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Mai-Britt Zocca Ph.D.
Headquarters: Copenhagen
Employees: 57
Exchange: NASDAQ

Keep an eye on IO Biotech

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is IO Biotech's (IOBT) price per share?

The current price per share for IO Biotech (IOBT) is $0.89. The stock has seen a price change of -$0.1 recently, indicating a -10.32% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for IO Biotech (IOBT)?

For IO Biotech (IOBT), the 52-week high is $2.1, which is 135.73% from the current price. The 52-week low is $0.73, the current price is 21.42% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is IO Biotech (IOBT) a growth stock?

IO Biotech (IOBT) has shown an average price growth of -3.55% over the past three years. It has received a score of 6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying IO Biotech as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is IO Biotech (IOBT) stock price performance year to date (YTD)?

As of the latest data, IO Biotech (IOBT) has a year-to-date price change of -53.4%. Over the past month, the stock has experienced a price change of -23.28%. Over the last three months, the change has been -36.43%. Over the past six months, the figure is -38.19%.

help

Is IO Biotech (IOBT) a profitable company?

IO Biotech (IOBT) has a net income of -$86.08M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$91.44M. Furthermore, the EBITDA is -$93.16M.

help

What is the market capitalization of IO Biotech (IOBT)?

IO Biotech (IOBT) has a market capitalization of $58.63M. The average daily trading volume is 0.93, indicating the stock's liquidity and investor engagement.

News

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

CONFERENCE CALLS/ WEBCASTS

May 23, 2024

IO Biotech to Present at Jefferies Global Healthcare Conference

EARNINGS RELEASES AND OPERATING RESULTS

May 14, 2024